Skip to main content
Figure 3 | Breast Cancer Research

Figure 3

From: Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer

Figure 3

PIK3CA mutation and phosphatase and tensin homolog loss confer sensitivity to phosphatidylinositol-3-kinase pathway inhibitors. PIK3CA mutation and phosphatase and tensin homolog (PTEN) loss confer sensitivity to phosphatidylinositol-3-kinase pathway inhibitors in estrogen-deprived estrogen-receptor-positive breast cancer cells. Cells cultured under estrogen-deprived conditions were treated with (a) 50 nmol/l BGT226, (b) 1 ╬╝mol/l BKM120 or (c) 30 nmol/l RAD001 and apoptosis was measured after 4 days of treatment by TUNEL flow cytometry. Results are from at least three replicates for each treatment condition per cell line. Significant induction of apoptosis by treatment with inhibitors is indicated (*P < 0.05). WT, wild-type.

Back to article page